Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ASPH | Q12797 | 1/20 | 0.31 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124193 | 0.84 | ACACB (0.35) | BACE1KDM4EALDH1A1 | |
| SCHEMBL1395991 | 0.77 | AGBL2 (0.41) | AGBL2BACE1BACE2DPP4DPP9 | |
| SCHEMBL219948 | 0.76 | AGBL2 (0.31) | AGBL2MEN1KMT2AALDH1A1 | |
| SCHEMBL12303874 | 0.74 | CES2 (0.35) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL29738141 | 0.73 | NPSR1 (0.43) | AGBL2MAPTKDM4EALDH1A1 | |
| SCHEMBL1418614 | 0.73 | BACE1 (0.40) | AGBL2BACE1KMT2ABACE2 | |
| SCHEMBL12780425 | 0.73 | AGBL2 (0.41) | AGBL2BACE1MEN1KMT2ADPP4 | |
| SCHEMBL644695 | 0.73 | NPSR1 (0.43) | AGBL2MAPTKDM4EALDH1A1 | |
| SCHEMBL30960477 | 0.72 | P4HTM (0.41) | KDM4EALDH1A1 | |
| SCHEMBL589521 | 0.72 | P4HTM (0.41) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383268-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| US-8835465-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2014-09-16 | — | — | US | disclosed |
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| US-8324252-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2012-12-04 | — | — | US | disclosed |
| CN-101155800-B | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB | 2012-05-23 | — | — | CN | disclosed |
| US-8114989-B2 | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2012-02-14 | — | — | US | disclosed |
| EP-2383268-A1 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | AstraZeneca AB (SE) | 2011-11-02 | — | — | EP | disclosed |
| EP-1846394-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA R&D (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| CN-101238116-A | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-08-06 | — | — | CN | disclosed |
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| CN-101155800-A | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2008-04-02 | — | — | CN | disclosed |
| EP-1846394-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082392-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | CNKSR1, LTK, MUSK | AGBL2 2995/4885BACE1 4527/4885MEN1 2827/4885 |
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | MAP3K19, MAP4K2, MAP3K2 | AGBL2 2369/4885BACE1 4489/4885MEN1 2609/4885 |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | AGBL2 1426/4885BACE1 4771/4885MEN1 2604/4885 |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ABL1, FLT3, ERBB2 | AGBL2 1426/4885BACE1 4771/4885MEN1 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.